Who are Hydroxyurea (HU)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gemzar, HYDROXYUREA, standard dose ARA-C, Gemcitabine Injectable Product, Cladribine Tablets, Platinum + Gemcitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroxyurea-hu.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Hydroxyurea (HU) — Competitive Intelligence Brief

Hydroxyurea (HU) (Hydroxyurea (HU)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; ribonucleotide reductase inhibitor. Area: Oncology; Hematology.

phase 3 Antimetabolite; ribonucleotide reductase inhibitor Ribonucleotide reductase Oncology; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Hydroxyurea (HU) (Hydroxyurea (HU)) — Bionoxx Inc.. Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydroxyurea (HU) TARGET	Hydroxyurea (HU)	Bionoxx Inc.	phase 3	Antimetabolite; ribonucleotide reductase inhibitor	Ribonucleotide reductase
Gemzar	Gemcitabine Hydrochloride	Accord Hlthcare	marketed	Nucleoside metabolic inhibitor	Ribonucleotide reductase; DNA incorporation	1996-01-01
HYDROXYUREA	HYDROXYUREA		marketed	Antimetabolite [EPC]	Ribonucleotide reductase	1967-01-01
standard dose ARA-C	standard dose ARA-C	National Research Center for Hematology, Russia	marketed	Nucleoside analog antimetabolite	DNA polymerase; ribonucleotide reductase
Gemcitabine Injectable Product	Gemcitabine Injectable Product	Henan Cancer Hospital	marketed	Nucleoside analog antimetabolite	Ribonucleotide reductase; DNA incorporation
Cladribine Tablets	Cladribine Tablets	Keith Edwards, M.D.	marketed	Purine nucleoside analog	Ribonucleotide reductase; DNA incorporation
Platinum + Gemcitabine	Platinum + Gemcitabine	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Chemotherapy combination (platinum agent + nucleoside analog)	DNA (platinum crosslinking); ribonucleotide reductase and DNA polymerase (gemcitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-06-28 — Gemzar · 12403086 · Formulation · US
2032-04-15 — Gemzar · 8679094 · Formulation · US
2033-07-01 — Gemzar · 9241948 · Formulation · US
2034-08-19 — Gemzar · 10729823 · Formulation · US
2034-08-19 — Gemzar · 12447241 · Formulation · US
2041-12-23 — HYDROXYUREA · 12409156 · Formulation · US

Sponsor landscape (Antimetabolite; ribonucleotide reductase inhibitor class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Bionoxx Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxyurea (HU) — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxyurea-hu. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab